Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Ebitda Margin ExpansionResults View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.5%Reaction day

₹2021.00

prior close

₹2043.10

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.3%+4.8% vs market

Pharmaceuticals peers, median of 147sector-0.9%+4.4% vs sector

On the reaction day the stock moved 4.8 pts more than Nifty Smallcap 250 and 4.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+0.3

15m

-0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.5-1.3+4.8-0.9+4.4

Next day

+4.2-0.8+5.0-0.6+4.8

+3.9-0.8+4.7-0.3+4.2

+6.9-0.2+7.0-0.6+7.4

+5.5-0.6+6.1-0.6+6.1

+6.5+0.7+5.7-0.9+7.4

+5.0+1.9+3.2-0.1+5.1

15d

+5.8+0.5+5.3-0.8+6.7

+7.6+1.1+6.5-1.0+8.6

-1.1+1.2-2.3-1.3+0.2

-3.7+1.6-5.3-4.7+1.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caplin Point Laboratories reported consolidated revenue from operations of ₹510.2 Crores in Q1 FY26, up 11.2% year-on-year, while total revenue rose 11.7% to ₹533.4 Crores. Profit after tax grew 20.7% YoY to ₹150.8 Crores, with PAT margin expanding to 28.3% from 26.2%. EBITDA jumped 17.9% to ₹200.9 Crores with margin expanding 200 basis points to 37.7%, and Basic EPS rose 23.1% to ₹20.10. The US business surged 36% YoY to ₹108.5 Crores. The Board recommended a final dividend of ₹3 (150%) per share for FY25, taking total FY25 dividend to ₹6 (300%). The company holds ₹1,237 Crores in free cash reserves and ₹2,207 Crores in liquid assets, and remains net cash positive while planning ₹1,000+ Crores in capex over the next 2-3 years. Auditor Brahmayya & Co. issued an unmodified review report.

Likely market impact

Strong, broad-based growth across revenue, profitability and margins with a clean audit report signals robust business health for shareholders. The doubled total dividend (300% vs FY24) and net cash-positive status with rising cash reserves provide downside protection and potential for further capital returns.